The Sydney W. Souers Endowed Chair, Professor and Chairman, Department of Neurology and Psychiatry, Saint Louis University
Psychiatry
Dr. Henry A. Nasrallah, MD
|
|
Give Review
Henry A. Nasrallah works in the field of Psychiatry. He over the years received 4 awards: "Distinguished Scholar Award", "NAMI Exemplary Psychiatrist Award", "U.S.A. Teacher of the Year" and "Best Doctors in America". Dr. Henry A. Nasrallah is a published doctor and has 101 publications published. The lastest was: 'Cognitive deficits distinguish patients with adolescent- and adult-onset schizophrenia.'
Publications
- Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy.
- Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies.
- Adjunctive Lisdexamfetamine Dimesylate Therapy in Adult Outpatients With Predominant Negative Symptoms of Schizophrenia: Open-Label and Randomized-Withdrawal Phases.
- Persistent infection with neurotropic herpes viruses and cognitive impairment.
- Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study.
- Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: Results from a ...
- 25 years of editing Schizophrenia Research: A unique and gratifying journey.
- On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not.
- Clinical Pharmacology of Paliperidone Palmitate A Parenteral Long-Acting Formulation for the Treatment of Schizophrenia.
- Antipsychotics, mortality and schizophrenia: What are the facts?
- Schizophrenia and obsessive-compulsive disorder.
- Linkage of cognitive impairments with metabolic disorders in schizophrenia.
- A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.
- Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.
- Neurological disorders in schizophrenia.
- Psychiatric and physical comorbidity in schizophrenia. Preface.
- Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia.
- Elevating the standard of care in the management of cardiometabolic risk factors in patients with mental illness. Conclusion: summary and recommendations.
- The urgent need for monitoring and intervention to reduce metabolic risk factors in patients with schizophrenia.
- Diagnosing and managing psychotic and mood disorders.
- Improving the pedagogy associated with the teaching of psychopharmacology.
- The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial.
- Introduction: evaluating the evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and beyond.
- Improving patient outcomes in schizophrenia: achieving remission.
- Raising the bar for treatment expectations in schizophrenia: achieving remission as a routine goal of antipsychotic pharmacotherapy.
- Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses.
- Time-dependent effects of haloperidol and ziprasidone on nerve growth factor, cholinergic neurons, and spatial learning in rats.
- Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies.
- Metabolic findings from the CATIE trial and their relation to tolerability.
- Pain insensitivity in schizophrenia: trait or state marker?
- Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder.
- Focus on lower risk of tardive dyskinesia with atypical antipsychotics.
- The influence of study design on the results of pharmacoepidemiologic studies of diabetes risk with antipsychotic therapy.
- Defining and measuring clinical effectiveness in the treatment of schizophrenia.
- An overview of common medical comorbidities in patients with schizophrenia.
- Neurologic comorbidities in schizophrenia.
- Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care.
- The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists.
- Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data.
- Risperidone in the treatment of delirium: results from a prospective open-label trial.
- Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone.
- Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics.
- Factors in antipsychotic drug selection: tolerability considerations.
- Schizophrenia and aging: no more dearth of data?
- Antipsychotic-induced type 2 diabetes: evidence from a large health plan database.
- Treatment of bipolar disorder.
- Pharmacoeconomic implications of adverse effects during antipsychotic drug therapy.
- Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
- Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia.
- Factors influencing phenothiazine-induced ECG changes.
- Perinatal complications and genetic loading in schizophrenia: preliminary findings.
- Unipolar vs. bipolar mania: a review of 247 patients.
- Cortical atrophy in young adults with a history of hyperactivity in childhood.
- Leukoaraiosis in asymptomatic adult offspring of individuals with Alzheimer's disease.
- Duration of illness and neuropsychological performance in asymptomatic HIV infection.
- Cognitive deficits distinguish patients with adolescent- and adult-onset schizophrenia.
- Developmental brain anomalies in schizophrenia and bipolar disorder: a controlled MRI study.
- Structural brain-imaging findings in affective disorders: an overview.
- Methodological issues in tardive dyskinesia research.
- Weight change during various neuropharmacologic manipulations in psychotic inpatients.
- Perinatal insult as a risk factor in paranoid and nonparanoid schizophrenia.
- Echocardiographic assessment of schizophrenics and manics: a reexamination of early necropsy findings.
- The impact of psychopharmacology education on prescribing practices.
- Hemispheric asymmetry in affective disorders.
- Effects of naloxone on cognitive deficits following electroconvulsive therapy.
- Correlation between plasma concentrations of chlorpromazine and clinical response.
- Seasonality of birth in subtypes of chronic schizophrenia.
- Motoric lateralization in schizophrenic males.
- Reversal of dexamethasone nonsuppression with sleep deprivation in primary depression.
- Haloperidol and an unrelated sudden death.
- Reserpine, serotonin, and schizophrenia.
- Statistical "noise" in CAT scan measurements.
- Left hemispheric density deficits in chronic schizophrenia.
- A histological study of the corpus callosum in chronic schizophrenia.
- Clinical correlates of sulcal widening in chronic schizophrenia.
- Leukocyte regulation in depression and schizophrenia.
- Clinical significance of large cerebral ventricles in manic males.
- Clinical differences between schizophrenic patients with and without large cerebral ventricles.
- Laterality shift in alcoholic males.
- Opiate antagonism fails to reverse post-ECT cognitive deficits.
- Depression, cortisol metabolism and lymphocytopenia.
- Visual evoked potential correlates of positive/negative symptoms in schizophrenia.
- Propranolol in high doses increases plasma prolactin concentrations in male rats.
- Psychopathology of corpus callosum tumors.
- Dexamethasone nonsuppression predicts the antidepressant effects of sleep deprivation.
- Cerebral ventricular enlargement in subtypes of chronic schizophrenia.
- Alcoholism secondary to essential tremor.
- Propranolol and prolactin.
- Change in neuropsychological performance in asymptomatic HIV infection: 1-year follow-up.
- Mass fragmentography of phenylethylamine, m- and p-tyramine and related amines in plasma, cerebrospinal fluid, urine, and brain.
- Effects of dopamine synthesis inhibition on WAIS comprehension.
- Relationships between brain density, cortical atrophy and ventriculomegaly in schizophrenia and mania.
- Tardive dyskinesia and depot fluphenazine.
- Tardive dyskinesia in a phantom limb.
- Sydenham''s chorea and psychopathology.
- The unintegrated right cerebral hemispheric consciousness as alien intruder: a possible mechanism for Schneiderian delusions in schizophrenia.
- Corpus callosum thickness in chronic schizophrenia.
- Neuropsychological performance and CD4 levels in HIV-1 asymptomatic infection.
- Psychopathology in human immunodeficiency virus infection: lifetime and current assessment.
- Neuropsychological performance in asymptomatic HIV infection.
Schools
American University of Beirut Faculty of Medicine
American University Med Center
University Rochester
Nimh
Doctors Specialties
- Geriatric Psychiatry
- Psychiatry
Accepted Insurances
Awards
- Distinguished Scholar Award
- NAMI Exemplary Psychiatrist Award
- U.S.A. Teacher of the Year
- Best Doctors in America
Education
-
University of Rochester -
American University of Beirut Faculty of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Michael R. Jarvis, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ahmad B. Ardekani, MD |
|
|
Dr. John S. Rabun Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Claude R. Cloninger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nuri B. Farber, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John W. Newcomer, MD |
|
|
Dr. Abhilash K. Desai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul M. Packman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Natasha M. Marrus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel A. Loiterstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert H. Rifkin, MD |
|
|
Dr. Keerthi Akkineni, MD |
|
|
Dr. Mudasir Asif, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tracy D. Gunter, MD |
|
|
Dr. Kevin J. Black, MD |
|
|
Dr. Steven A. Harvey, MD |
|
|
Dr. Briana K. Lester, MD |